NDAORALFILMPriority Review
Lifecycle
Pre-Launch
Clinical Trials
20
Data completeness
3/8 — Basic
Priority Review
DOLUTEGRAVIR (dolutegravir) by Inpharmus is fixed-dose combination of the hiv‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see microbiology ()]. Approved for hiv infection, mother to child transmission, hiv/hepatitis coinfection and 2 more indications.
Drug data last refreshed 2w ago
Mechanism of Action
fixed-dose combination of the HIV‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see Microbiology ()].
Worked on DOLUTEGRAVIR at Inpharmus? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.